Shang Liqun, Zhang Wei, Wu Hua, Wu Runmiao, Chen Ruilin
Department of Respiratory and Critical Care Medicine, Shaanxi Provincial People's Hospital, Xian 710068, China.
Evid Based Complement Alternat Med. 2021 Oct 14;2021:1436088. doi: 10.1155/2021/1436088. eCollection 2021.
To explore the diagnostic value of FTO combined with CEA or CYFRA21-1 for nonsmall cell lung cancer (NSCLC) and to provide a theoretical basis for molecular diagnosis of NSCLC.
Totally, 60 patients with nonsmall cell lung cancer (NSCLC) treated in our hospital between Feb. 2018 and Feb. 2019 were enrolled into the patient group (Pat group) and 50 healthy individuals with normal physical examination results in our hospital over the same time span into the control group (Con group). Serum of each participant was collected, and then qRT-PCR was adopted for quantification of serum FTO and the chemiluminescence method for quantification of serum CEA and CYFRA21-1. Additionally, corresponding ROC curves were drawn for diagnostic value analyses of FTO, CEA, and CYFRA21-1 in NSCLC and Cox regression analysis was performed for analysis of independent factors impacting the patients' 3-year prognosis.
The Pat group presented notably higher FTO, CEA, and CYFRA21-1 levels than the Con group (all < 0.05), and patients with a high FTO level faced notably higher probabilities of stage III + IV and lymph node metastasis (LNM) (both < 0.05). Additionally, according to ROC curve-based analysis, with a high level in patients with NSCLC, FTO had high specificity and sensitivity in diagnosing NSCLC; joint detection of it with CEA or YFRA21-1 demonstrated a higher sensitivity in NSCLC diagnosis and presented a higher specificity in diagnosing early NSCLC compared with detection of CEA or YFRA21-1 alone. According to Cox regression analysis, clinical stage, LNM, and FTO were independent risk factors impacting the prognosis of patients with LC (all < 0.05).
FTO presents a high level in NSCLC cases, and joint detection of it with CEA or CYFRA21-1 delivered a higher specificity in diagnosing NSCLC in contrast to detection of CEA or YFRA21-1 alone, so the joint detection is worth popularizing in clinical scenarios.
探讨FTO联合癌胚抗原（CEA）或细胞角蛋白19片段（CYFRA21-1）对非小细胞肺癌（NSCLC）的诊断价值，为NSCLC的分子诊断提供理论依据。
选取2018年2月至2019年2月在我院接受治疗的60例非小细胞肺癌患者作为患者组（Pat组），选取同期在我院体检结果正常的50例健康个体作为对照组（Con组）。采集每位参与者的血清，采用qRT-PCR法对血清FTO进行定量，采用化学发光法对血清CEA和CYFRA21-1进行定量。此外，绘制相应的ROC曲线，对FTO、CEA和CYFRA21-1在NSCLC中的诊断价值进行分析，并进行Cox回归分析，以分析影响患者3年预后的独立因素。
Pat组的FTO、CEA和CYFRA21-1水平显著高于Con组（均P<0.05），FTO水平高的患者发生Ⅲ+Ⅳ期和淋巴结转移（LNM）的概率显著更高（均P<0.05）。此外，根据基于ROC曲线的分析，NSCLC患者FTO水平高时，其对NSCLC的诊断具有较高的特异性和敏感性；与单独检测CEA或CYFRA21-1相比，FTO与CEA或YFRA21-1联合检测在NSCLC诊断中显示出更高的敏感性，在早期NSCLC诊断中具有更高的特异性。根据Cox回归分析，临床分期、LNM和FTO是影响肺癌患者预后的独立危险因素（均P<0.05）。
FTO在NSCLC病例中水平较高，与单独检测CEA或CYFRA21-1相比，FTO与CEA或CYFRA21-1联合检测在NSCLC诊断中具有更高的特异性，因此联合检测值得在临床中推广。
